These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28393726)

  • 81. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
    Walter E; Voit M; Eichhober G
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):265-275. PubMed ID: 32700584
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation.
    Biskupiak J; Ghate SR; Jiao T; Brixner D
    J Manag Care Pharm; 2013; 19(9):789-98. PubMed ID: 24156648
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 86. New oral anticoagulants for the treatment of venous thromboembolism.
    Agnelli G; Becattini C; Franco L
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB
    Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.
    Reddy VY; Akehurst RL; Amorosi SL; Gavaghan MB; Hertz DS; Holmes DR
    Stroke; 2018 Jun; 49(6):1464-1470. PubMed ID: 29739915
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y; Coupland C; Hill T; Hippisley-Cox J
    BMJ; 2018 Jul; 362():k2505. PubMed ID: 29973392
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
    Amin A; Stokes M; Makenbaeva D; Wiederkehr D; Wu N; Lawrence JH
    J Med Econ; 2014 Nov; 17(11):771-81. PubMed ID: 25133458
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Direct Oral Anticoagulant as a Cost Effective Alternative to Warfarin for Treatment of Provoked Venous Thrombosis.
    Courtney W; Groarke E; Conway J; Conway E; Bourke D; Saunders J; Watts M; O'Keefe D
    Ir Med J; 2016 Oct; 109(9):466. PubMed ID: 28125180
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism.
    Lim MS; Nandurkar D; Jong I; Cummins A; Tran H; Chunilal S
    J Thromb Thrombolysis; 2020 Feb; 49(2):220-227. PubMed ID: 31493288
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center.
    Ergül E; Yılmazel Uçar E; Araz Ö; Aksakal A; Kerget B; Sağlam L
    Tuberk Toraks; 2023 Dec; 71(4):390-399. PubMed ID: 38152009
    [TBL] [Abstract][Full Text] [Related]  

  • 96. An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug.
    D'Elia E; Gori M; Grosu A; Iorio A; Lorini FL; Falanga A; Di Marco F; Senni M
    BMC Pulm Med; 2021 Mar; 21(1):102. PubMed ID: 33761886
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.
    Albaladejo P; Samama CM; Sié P; Kauffmann S; Mémier V; Suchon P; Viallon A; David JS; Gruel Y; Bellamy L; de Maistre E; Romegoux P; Thoret S; Pernod G; Bosson JL;
    Anesthesiology; 2017 Jul; 127(1):111-120. PubMed ID: 28410272
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Management of bleeding or urgent interventions in patients treated with direct oral anticoagulants: 2017 recommendations for Poland.
    Pruszczyk P; Tomaszuk-Kazberuk A; Słowik A; Drwiła R; Rydzewska G; Filipiak KJ; Gaciong Z; Kaźmierczak J; Marczyński W; Windyga J; Kobayashi A; Stepińska J
    Pol Arch Intern Med; 2017 May; 127(5):343-351. PubMed ID: 28400546
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review.
    De Caterina R; Lip GYH
    Clin Res Cardiol; 2017 Aug; 106(8):565-572. PubMed ID: 28396988
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.